OpGen (OPGN) Competitors $4.89 0.00 (0.00%) As of 05/20/2025 12:55 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsSEC FilingsTrendsBuy This Stock OPGN vs. DCGO, EUDA, XGN, CORBF, ATPC, SERA, KDLY, QIPT, PIII, and BDSXShould you be buying OpGen stock or one of its competitors? The main competitors of OpGen include DocGo (DCGO), EUDA Health (EUDA), Exagen (XGN), Global Cord Blood (CORBF), Agape ATP (ATPC), Sera Prognostics (SERA), Kindly MD (KDLY), Quipt Home Medical (QIPT), P3 Health Partners (PIII), and Biodesix (BDSX). These companies are all part of the "healthcare" industry. OpGen vs. DocGo EUDA Health Exagen Global Cord Blood Agape ATP Sera Prognostics Kindly MD Quipt Home Medical P3 Health Partners Biodesix DocGo (NASDAQ:DCGO) and OpGen (NASDAQ:OPGN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, community ranking, dividends, analyst recommendations, earnings, profitability and institutional ownership. Does the MarketBeat Community believe in DCGO or OPGN? OpGen received 252 more outperform votes than DocGo when rated by MarketBeat users. However, 73.13% of users gave DocGo an outperform vote while only 51.81% of users gave OpGen an outperform vote. CompanyUnderperformOutperformDocGoOutperform Votes4973.13% Underperform Votes1826.87% OpGenOutperform Votes30151.81% Underperform Votes28048.19% Which has preferable earnings and valuation, DCGO or OPGN? DocGo has higher revenue and earnings than OpGen. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDocGo$520.50M0.27$6.86M-$0.02-69.50OpGen$2.67M18.42-$32.67MN/AN/A Which has more volatility and risk, DCGO or OPGN? DocGo has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500. Comparatively, OpGen has a beta of -1.71, meaning that its stock price is 271% less volatile than the S&P 500. Do analysts recommend DCGO or OPGN? DocGo presently has a consensus price target of $3.56, indicating a potential upside of 156.12%. Given DocGo's stronger consensus rating and higher possible upside, analysts plainly believe DocGo is more favorable than OpGen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DocGo 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50OpGen 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is DCGO or OPGN more profitable? DocGo has a net margin of 4.35% compared to OpGen's net margin of -1,140.36%. DocGo's return on equity of 8.90% beat OpGen's return on equity.Company Net Margins Return on Equity Return on Assets DocGo4.35% 8.90% 5.72% OpGen -1,140.36%N/A -287.58% Does the media refer more to DCGO or OPGN? In the previous week, DocGo had 15 more articles in the media than OpGen. MarketBeat recorded 16 mentions for DocGo and 1 mentions for OpGen. DocGo's average media sentiment score of 0.75 beat OpGen's score of -0.36 indicating that DocGo is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DocGo 6 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive OpGen 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders have more ownership in DCGO or OPGN? 56.4% of DocGo shares are owned by institutional investors. Comparatively, 2.7% of OpGen shares are owned by institutional investors. 2.7% of DocGo shares are owned by company insiders. Comparatively, 43.8% of OpGen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryDocGo beats OpGen on 13 of the 16 factors compared between the two stocks. Get OpGen News Delivered to You Automatically Sign up to receive the latest news and ratings for OPGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OPGN vs. The Competition Export to ExcelMetricOpGenMedical laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$49.23M$3.00B$5.43B$8.48BDividend YieldN/A31.24%5.22%4.11%P/E RatioN/A13.2326.7920.05Price / Sales18.42164.59394.72116.44Price / CashN/A57.5638.2534.62Price / Book-0.424.316.864.61Net Income-$32.67M-$22.21M$3.22B$248.19M7 Day Performance4.04%3.62%6.83%2.97%1 Month Performance17.83%7.44%13.73%16.58%1 Year Performance41.33%4.26%18.22%8.16% OpGen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OPGNOpGenN/A$4.89flatN/A+26.7%$49.23M$2.67M0.00100Analyst ForecastDCGODocGo3.7383 of 5 stars$1.45-1.4%$3.56+145.5%-54.3%$147.88M$520.50M5.182,920EUDAEUDA HealthN/A$3.88+1.6%N/A+67.2%$144.15M$4.01M0.002XGNExagen4.6444 of 5 stars$6.33+5.3%$7.50+18.5%+218.7%$134.83M$56.72M-6.73220Analyst RevisionHigh Trading VolumeCORBFGlobal Cord BloodN/A$1.05-3.7%N/A-56.0%$127.63M$196.12M0.001,200ATPCAgape ATP0.4327 of 5 stars$2.03-1.0%N/A-57.0%$101.51M$1.32M-2.7840Earnings ReportSERASera Prognostics1.1819 of 5 stars$2.32+0.4%N/A-74.8%$87.38M$115,000.00-2.34120Positive NewsEarnings ReportKDLYKindly MD1.111 of 5 stars$13.96+7.8%N/AN/A$77.99M$2.47M-18.13N/AQIPTQuipt Home Medical1.5582 of 5 stars$1.40-1.1%$2.85+104.3%-33.7%$60.11M$244.72M-8.21800Gap UpPIIIP3 Health Partners2.2504 of 5 stars$7.94-0.6%$16.25+104.7%-70.6%$57.03M$1.50B-9.45500Earnings ReportBDSXBiodesix2.593 of 5 stars$0.30-0.1%$2.00+564.5%-82.8%$44.12M$71.32M-0.77220Gap DownHigh Trading Volume Related Companies and Tools Related Companies DCGO Competitors EUDA Competitors XGN Competitors CORBF Competitors ATPC Competitors SERA Competitors KDLY Competitors QIPT Competitors PIII Competitors BDSX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OPGN) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OpGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share OpGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.